To store the coronavirus vaccine, a temperature regime of -70 Celsius is required, which causes technical difficulties. At the same time, the price for the vaccine is promised below the market price.
US-based Pfizer will not be shipping its coronavirus vaccine anytime soon. Its availability will be limited due to special storage conditions - requirements for a temperature regime of -70 Celsius. This was announced on Tuesday, November 10, according to Reuters.
In addition, Pfizer and BioNTech will still need to obtain regulatory approval. It is assumed that the first to receive the vaccine will be health workers and at-risk groups.
At the same time, the complex requirements for the vaccine and its ultra-cold storage can be a barrier for even the most modern hospitals in the United States, not to mention its availability in poor countries with limited resources.
The main problem is that a vaccine that uses synthetic mRNA to activate the immune system must be stored at -70 Celsius.
"The cold chain will be one of the most challenging aspects of vaccination. It will be a challenge in any setting because hospitals, even in large cities, do not have vaccine storage facilities at such ultra-low temperatures," said Amesh Adal, a senior fellow at the Johns Hopkins Center for Health Security.
The company said the delivery could be done using dry ice.
At the same time, the price of the vaccine from BioNTech and Pfizer will be below market value. Also, prices will be differentiated between countries and regions. This was announced by Ryan Richardson, Strategic Director of BioNTech.